-
Je něco špatně v tomto záznamu ?
Late-stage labeling of diverse peptides and proteins with iodine-125
A. Marek, B. Brož, M. Kriegelstein, G. Nováková, J. Hojcsková, M. Blechová, L. Žáková, J. Jiráček, L. Maletínská
Status neindexováno Jazyk angličtina Země Čína
Typ dokumentu časopisecké články, přehledy
NLK
Directory of Open Access Journals
od 2011
Free Medical Journals
od 2011
PubMed Central
od 2011
Europe PubMed Central
od 2011
ProQuest Central
od 2017-02-01
Open Access Digital Library
od 2011-02-01
Open Access Digital Library
od 2011-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2011
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
The preparation of specifically iodine-125 (125I)-labeled peptides of high purity and specific activity represents a key tool for the detailed characterization of their binding properties in interaction with their binding partners. Early synthetic methods for the incorporation of iodine faced challenges such as harsh reaction conditions, the use of strong oxidants and low reproducibility. Herein, we review well-established radiolabeling strategies available to incorporate radionuclide into a protein of interest, and our long-term experience with a mild, simple and generally applicable technique of 125I late-stage-labeling of biomolecules using the Pierce iodination reagent for the direct solid-phase oxidation of radioactive iodide. General recommendations, tips, and details of optimized chromatographic conditions to isolate pure, specifically 125I-mono-labeled biomolecules are illustrated on a diverse series of (poly)peptides, ranging up to 7.6 kDa and 67 amino acids (aa). These series include peptides that contain at least one tyrosine or histidine residue, along with those featuring disulfide crosslinking or lipophilic derivatization. This mild and straightforward late-stage-labeling technique is easily applicable to longer and more sensitive proteins, as demonstrated in the cases of the insulin-like growth factor binding protein-3 (IGF-BP-3) (29 kDa and 264 aa) and the acid-labile subunit (ALS) (93 kDa and 578 aa).
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25020886
- 003
- CZ-PrNML
- 005
- 20251014150437.0
- 007
- ta
- 008
- 251007s2025 cc f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jpha.2025.101198 $2 doi
- 035 __
- $a (PubMed)40741338
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a cc
- 100 1_
- $a Marek, Aleš $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, 16610, Czech Republic
- 245 10
- $a Late-stage labeling of diverse peptides and proteins with iodine-125 / $c A. Marek, B. Brož, M. Kriegelstein, G. Nováková, J. Hojcsková, M. Blechová, L. Žáková, J. Jiráček, L. Maletínská
- 520 9_
- $a The preparation of specifically iodine-125 (125I)-labeled peptides of high purity and specific activity represents a key tool for the detailed characterization of their binding properties in interaction with their binding partners. Early synthetic methods for the incorporation of iodine faced challenges such as harsh reaction conditions, the use of strong oxidants and low reproducibility. Herein, we review well-established radiolabeling strategies available to incorporate radionuclide into a protein of interest, and our long-term experience with a mild, simple and generally applicable technique of 125I late-stage-labeling of biomolecules using the Pierce iodination reagent for the direct solid-phase oxidation of radioactive iodide. General recommendations, tips, and details of optimized chromatographic conditions to isolate pure, specifically 125I-mono-labeled biomolecules are illustrated on a diverse series of (poly)peptides, ranging up to 7.6 kDa and 67 amino acids (aa). These series include peptides that contain at least one tyrosine or histidine residue, along with those featuring disulfide crosslinking or lipophilic derivatization. This mild and straightforward late-stage-labeling technique is easily applicable to longer and more sensitive proteins, as demonstrated in the cases of the insulin-like growth factor binding protein-3 (IGF-BP-3) (29 kDa and 264 aa) and the acid-labile subunit (ALS) (93 kDa and 578 aa).
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Brož, Břetislav $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, 16610, Czech Republic
- 700 1_
- $a Kriegelstein, Michal $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, 16610, Czech Republic
- 700 1_
- $a Nováková, Gabriela $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, 16610, Czech Republic
- 700 1_
- $a Hojcsková, Jana $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, 16610, Czech Republic
- 700 1_
- $a Blechová, Miroslava $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, 16610, Czech Republic
- 700 1_
- $a Žáková, Lenka $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, 16610, Czech Republic
- 700 1_
- $a Jiráček, Jiří $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, 16610, Czech Republic
- 700 1_
- $a Maletínská, Lenka $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, 16610, Czech Republic
- 773 0_
- $w MED00205566 $t Journal of pharmaceutical analysis $x 2214-0883 $g Roč. 15, č. 7 (2025), s. 101198
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/40741338 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20251007 $b ABA008
- 991 __
- $a 20251014150443 $b ABA008
- 999 __
- $a ok $b bmc $g 2410956 $s 1259042
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2025 $b 15 $c 7 $d 101198 $e 20250117 $i 2214-0883 $m Journal of pharmaceutical analysis $n J Pharm Anal $x MED00205566
- LZP __
- $a Pubmed-20251007